Stay updated with breaking news from Mobile Android. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN FRANCISCO — Treatment with imatinib resulted in a sustained clinical benefit after 90 days in hospitalized patients with hypoxemic COVID-19, according to results of the CounterCOVID study.At the American Thoracic Society International Conference, Job R. Schippers, MD-PhD candidate for pulmonary medicine at Amsterdam University Medical Center, presented long-term clinical outcomes at 90
I often hear, “Hey, I know you from Twitter!” as I turn on my heels to identify the source. A variation of this exclamation has become commonplace at scientific conferences. Particularly in a time characterized by so much distance, the use of social media can be helpful for connecting with new areas of scholarship, fellow scientists and the people most affected by the work we do.
Although the development and use of biomarkers in liver transplantation has progressed in recent years, challenges and limitations remain, according to presenters at the American Transplant Congress 2022. Thomas D. Schiano, MD, professor of medicine and liver diseases at Mount Sinai in New York, told attendees that among transplant patients, biomarkers should monitor short- and long-term
Patients with psoriatic arthritis treated with bimekizumab demonstrated improvements across joint and skin parameters compared with placebo, according to Phase 3 clinical trial data presented at the EULAR 2022 Congress.“I am delighted to be able to present these very exciting Phase 3 data from the BE COMPLETE study of this inhibitor of both IL-17A and -F,” Joseph F. Merola, MD, of
The FDA has approved rituximab-arrx, in combination with methotrexate, in adult patients with moderate or severely active rheumatoid arthritis who have had inadequate responses to one or more TNF agonist therapies. Rituximab-arrx (Riabni, Amgen), a biosimilar to rituximab (Rituxan, Genentech) was previously approved for indications including non-Hodgkin’s lymphoma, chronic lymphocytic